Résumé
OBJECTIVE: To summarize the structural design strategy and safety assessments of rAAV packaging systems. METHODS: Based on the research progress and international review experience of commercial rAAV products, the design strategy and safety assessments of rAAV packaging systems were summarized. The design strategy and safety assessments of rAAV packaging systems were summarized. RESULTS: The scientific evaluation of the pharmaceutical design of rAAV for human should cover multiple aspects, because various types of AAVs differ in tissue selectivity, viral assembly, transgene expression. Meanwhile, the packaging system is diverse, and the production process is complex. CONCLUSION: The considerations referring to the rAAV structure and mechanisms of producing replication-competent AAV are proposed, and we hope to improve the communications between developers and regulators.